Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 10/27/20

Other CTEP-Related Initiatives

NCI Announces Funding for Development of Standardized Electronic Treatment Plans for NCI-Supported Clinical Trials Applicable across Clinical Research Sites

NCTN/NCORP Data Archive: Expanding Access to Clinical Trial Data

New Approaches to Neuroblastoma Therapy

Coordinating Center for Clinical Trials (CCCT)

The Coordinating Center for Clinical Trials (CCCT) plays a key role in supporting NCI’s clinical and translational research programs to advance science and patient care. More…

Pharmaceutical Collaborations

The goal of the Cancer Therapy Evaluation Program (CTEP) is to facilitate the process of bringing promising, novel, investigational anticancer agents to the public as quickly and as safely as possible. As part of meeting that goal, CTEP actively seeks collaborations with pharmaceutical and biotechnology companies, specifically to complement or enhance their clinical development plans, thereby expediting the development of promising agents. More…

The Children’s Oncology Group (COG) Phase I/Pilot Consortium

The consortium’s primary objective is to expeditiously develop and implement pediatric phase I and pilot studies, thus facilitating the integration of advances in cancer biology and therapy into the treatment of childhood cancer. The consortium includes approximately 20 pediatric COG institutions with expertise and experience in developmental therapeutics. More…

Central Institutional Review Board Initiative (CIRB)

The Central Institutional Review Board Initiative (CIRB) provides an innovative approach to human subject protection through a “facilitated review” process that streamlines local IRB review of adult and pediatric national multi-center cancer treatment trials. More…

Pediatric Preclinical Testing Consortium (PPTC)

The NCI-supported Pediatric Preclinical Testing Consortium (PPTC) is a program to systematically evaluate novel agents against genomically characterized childhood cancer solid tumor and leukemia in vivo models. More…

Michaele C. Christian Oncology Development Lectureship and Award

This award was established by the Cancer Therapy Evaluation Program in 2007 to honor the twenty year NCI career of Michaele C. Christian. Dr. Christian was appointed Associate Director of the Cancer Therapy Evaluation Program of DCTD in 1997 after serving as head of the Investigational Drug Branch overseeing the clinical development of novel anticancer agents. More…

The Childhood Cancer Survivor Study

The Childhood Cancer Survivor Study (CCSS) is a collaborative, multi-institutional study funded by the National Cancer Institute since 1993. The goal of CCSS is to investigate the long-term morbidity and mortality associated with the treatment regimens for children and adolescents treated for cancer during the past 30 years. More…

Collaboration with NHLBI on the BMT-CTN

The Blood and Marrow Clinical Trials Network (BMT CTN) is supported by a U01 grant to the NHLBI and NCI, with the NHLBI as the lead institute. NIAID also supports one of the trials. This network is managed jointly among NHLBI and NCI/CTEP program officers. More…

CTEP Early Drug Development (EDD) Meeting

The Cancer Therapy Evaluation Program (CTEP) sponsors an annual investigator meeting in the fall of each year. The meeting is intended as an educational event and is focused on enhancing communications between the NCI and the network of CTEP-supported ECTCN-funded early clinical trial investigators. More…

Adult Brain Tumor Consortium

The Adult Brain Tumor Consortium (ABTC) is a multi-institutional consortium that is supported through a UM1 Cooperative Agreement from the NCI. The consortium performs innovative, multidisciplinary
Phase 1 - 2 clinical trials that focus predominantly on adult patients with grade IV gliomas (glioblastoma multiforme). More…

Pediatric Brain Tumor Consortium (PBTC)

The primary objective of the PBTC is to rapidly conduct phase 1 and 2 clinical evaluations of new therapeutic drugs, intrathecal agents, delivery technologies, biological therapies, and radiation treatment strategies in children age 0 – 21 years of age with primary CNS tumors. More…